Abbott India: Should You Buy, Hold, or Sell Right Now?
- September 2, 2026
- Posted by: Lakshit Sharma
- Category: Market
Abbott India share price Rs 26,105 (NSE), up 0.99% today. 52-week range Rs 25,150 to Rs 32,775. PE 34x versus sector 51x. Q1 FY27 profit up 17.13% YoY to Rs 428.52 crore.
Quick Answer
Abbott India share price is trading around Rs 26,105, roughly 20 percent below its 52-week high of Rs 32,775 but comfortably above its 52-week low of Rs 25,150. The stock trades at 34 times earnings, actually a discount to the pharmaceutical industry average near 51 times, while return on equity stands at a strong 32.51 percent. Q1 FY27 net profit rose 17.13 percent year on year to Rs 428.52 crore on 4.33 percent revenue growth to Rs 1,813 crore. Long term holders may see the current price as a reasonable point to stay invested, while new buyers can weigh the modest revenue growth against the stock’s still-premium absolute price tag.
Abbott India share price has pulled back meaningfully from its 52-week high of Rs 32,775, and the Abbott India share price now trades near Rs 26,105 on the NSE. That still sits comfortably above the 52-week low of Rs 25,150, leaving investors asking whether this pharmaceutical major is a stock to buy at current levels, hold for its steady compounding, or trim given slowing revenue growth.
This Abbott India stock analysis walks through the latest Q1 FY27 results, valuation multiples versus the pharma sector, shareholding pattern and the technical setup, before laying out the Abbott India buy or sell case in plain terms. All figures below are drawn from exchange filings and public disclosures.
Click Here – Get Free Investment Predictions
About Abbott India
That context matters when weighing Abbott India share price against peers. Before deciding on Abbott India share price, it helps to understand the underlying business. Abbott India Ltd. is the Indian listed arm of US-based Abbott Laboratories, one of the country’s oldest and most established pharmaceutical companies, present in India for over seven decades. The company sells a diversified portfolio of branded generics across gastroenterology, women’s health, cardiology, and metabolic disorders, among other therapeutic areas.
Abbott India has a long history of consistent profitability and high dividend payouts, funded largely from operating cash flow rather than debt, reflected in a debt to equity ratio of just 0.04. The company recently saw a leadership change, with Sudarshan Jain appointed Chairman effective August 2026, replacing Munir Shaikh.
Abbott India Share Price Today: Key Levels
The table below summarises where Abbott India share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Abbott India CMP (NSE) | Rs 26,105 |
| Abbott India CMP (BSE) | Rs 26,105 |
| Day’s Change | +0.99% (Rs +255) |
| 52-Week High | Rs 32,775 |
| 52-Week Low | Rs 25,150 |
| Market Capitalisation | Approximately Rs 54,944 crore |
| NSE Volume (latest session) | 5,251 shares |
Abbott India share price is currently trading closer to the lower half of its 52-week band, having corrected from its all-time high levels seen earlier in the year, even as the underlying business keeps growing profits at a double digit pace.
Check the Univest Screener for Live Stock Data
Abbott India Financial Performance
These results are the single biggest driver of Abbott India share price in the near term. The Abbott India share price trend is closely tied to how these numbers evolve each quarter. Abbott India’s revenue from operations rose 4.33 percent year on year to Rs 1,813 crore in the June 2026 quarter (Q1 FY27), a modest but steady pace for a mature pharmaceutical business. Net profit grew faster, up 17.13 percent year on year to Rs 428.52 crore, aided by a 7.72 percent sequential rise in profit before tax from Q4 FY26. Quarterly EPS came in at Rs 201.66, up from Rs 172.17 a year earlier.
For the full year FY25, Abbott India had reported net profit of Rs 1,414.44 crore on revenue of Rs 6,409 crore, both up double digits year on year, underscoring the company’s track record of translating modest sales growth into stronger profit growth through operating leverage and cost discipline.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 1,813 crore | Rs 428.52 crore | +17.13% YoY profit growth |
| FY25 (full year) | Rs 6,409 crore | Rs 1,414.44 crore | +17.7% YoY profit growth |
Valuation Check: Is Abbott India Share Price Expensive?
Investors comparing Abbott India share price with peers usually start here. Any view on Abbott India share price should start from these valuation multiples. Abbott India share price currently reflects a price to earnings ratio of about 34 times trailing earnings, which is actually a discount to the broader pharmaceutical industry average of roughly 51 times. The price to book ratio stands near 11.5 times, supported by a strong 32.51 percent return on equity, well above what most industrial or consumer companies deliver.
The balance sheet carries almost no debt, with a debt to equity ratio of just 0.04, and the stock offers a dividend yield of 2.54 percent, funded by a high payout ratio of around 72 percent of profit. Historically, high-payout, low-debt pharma franchises like this have traded at premium multiples, so the current discount to sector PE is worth understanding rather than assuming it signals undervaluation outright, since payout ratios this high can sometimes limit reinvestment for growth.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Abbott India share price. Abbott India share price is currently positioned roughly 20 percent below its 52-week high of Rs 32,775 and about 4 percent above its 52-week low of Rs 25,150, placing it in the lower half of its annual trading range. A stock trading closer to its 52-week low than its high, following a stretch of muted single-digit revenue growth, often reflects the market re-rating growth expectations rather than a fundamental change in business quality.
Trading volumes on Abbott India remain modest given its high per-share price and relatively small free float, so investors should track the stock over several sessions rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Abbott India’s live price and technical levels.
Shareholding Pattern
This is a useful lens for reading Abbott India share price over time. Shifts here can influence Abbott India share price more than headline news on some sessions. As of June 2026, promoters hold approximately 74.99 percent of Abbott India, unchanged over recent quarters, reflecting the parent Abbott Laboratories’ long-term commitment to the Indian listing. Domestic institutional investors hold around 8.78 percent, while public shareholders account for roughly 13.41 percent of the equity.
This concentrated promoter holding, combined with a limited free float, means Abbott India share price can see outsized moves on relatively modest trading volumes compared with more widely held large-cap stocks.
Why Investors Are Watching Abbott India
- Debt free, high-payout balance sheet: A debt to equity ratio of just 0.04 and a dividend payout near 72 percent of profit reflect a capital-light, cash-generative business model.
- Strong return on equity: A 32.51 percent ROE places Abbott India among the more efficient users of shareholder capital in the pharma sector.
- Consistent double-digit profit growth: Q1 FY27 profit grew 17.13 percent YoY, continuing a multi-year trend of profit growth outpacing revenue growth.
- Valuation discount to sector: A 34x PE against a 51x industry average leaves room for re-rating if growth accelerates.
- New leadership: Sudarshan Jain’s appointment as Chairman in August 2026 brings fresh strategic direction to the company.
Risks and Factors to Watch
- Slowing revenue growth: Revenue grew just 4.33 percent YoY in Q1 FY27, a much slower pace than profit growth, and sustained single-digit topline growth could eventually cap earnings expansion.
- High payout limits reinvestment: A payout ratio near 72 to 79 percent of profit and free cash flow leaves less capital for aggressive new product investment relative to some peers.
- Premium absolute share price with limited liquidity: A high per-share price and concentrated promoter holding can mean sharper price swings on modest volumes.
- Sector-wide pricing and regulatory pressure: Like all Indian pharma companies, Abbott India is exposed to periodic drug pricing regulation and policy changes that can affect specific product categories.
Abbott India Share Price Target: What the Data Suggests
That is a key gap in the public data on Abbott India share price today. Until then, Abbott India share price remains best tracked through live, verified data rather than a single fixed number. Abbott India does not carry the dense sell-side analyst coverage seen in some large-cap sectors, so a single widely published consensus 12-month share price target is not consistently available across brokerages for this stock. What the data shows clearly is a business trading at a discount to its sector PE despite a return on equity well above sector norms.
Historically, steady compounders like Abbott India tend to re-rate when revenue growth reaccelerates from the low single digits seen recently. Investors who want live, updated research coverage can check the Univest Screener rather than anchoring to one fixed number, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Abbott India: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Abbott India share price right now. The Abbott India buy or sell decision depends heavily on whether you value steady, low-risk compounding over rapid growth, and how you weigh the current discount to sector valuation.
The case for buying: Long term investors who prioritise a debt free balance sheet, a 32.51 percent ROE and consistent dividend income may see the pullback to Rs 26,105, well off the 52-week high, as a reasonable entry point into a steady pharmaceutical compounder.
The case for holding: Existing shareholders benefiting from Abbott India’s high dividend payout and profit growth may prefer to stay invested, especially given the stock’s historical resilience through market cycles.
The case for trimming or waiting: Investors concerned about the slowdown in revenue growth to just 4.33 percent, or who want to see a clearer re-rating catalyst before committing fresh capital, may prefer to wait for stronger topline momentum.
Historically, quality pharmaceutical franchises with strong return ratios have rewarded patient investors, but a valuation discount can persist for a long time if growth stays muted, so match any decision to your own investment horizon and consult a SEBI-registered investment adviser if unsure.
Conclusion
Abbott India share price reflects a financially strong, debt free pharmaceutical business trading at a discount to its sector on PE, with a high return on equity and consistent dividend payouts, but also one facing a recent slowdown in revenue growth. Whether that combination makes the stock a buy, a hold or a candidate to trim depends on your own time horizon and growth expectations. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Abbott India a good stock to buy right now?
Ans. Abbott India combines a debt free balance sheet, a 32.51 percent return on equity and a valuation discount to the pharma sector, which appeals to long term investors. However, revenue growth of just 4.33 percent YoY in Q1 FY27 means growth-focused investors may want to see faster topline momentum before buying.
Q2. What is the Abbott India share price today?
Ans. Abbott India share price is trading around Rs 26,105 on the NSE, up about 0.99 percent on the day. The stock’s 52-week high is Rs 32,775 and its 52-week low is Rs 25,150.
Q3. What is the Abbott India share price target?
Ans. Abbott India does not have a single widely published analyst consensus 12-month share price target across brokerages. Investors can track live research and target updates on the Univest Screener and should consult a SEBI-registered adviser for a personalised view.
Q4. Why did Abbott India profit rise in Q1 FY27?
Ans. Abbott India’s Q1 FY27 net profit rose 17.13 percent year on year to Rs 428.52 crore, supported by a 4.33 percent rise in revenue to Rs 1,813 crore and a 7.72 percent sequential increase in profit before tax.
Q5. What is Abbott India’s market capitalisation and PE ratio?
Ans. Abbott India has a market capitalisation of approximately Rs 54,944 crore and trades at a price to earnings ratio of about 34 times, a discount to the industry average PE of roughly 51 times. Its return on equity is 32.51 percent and dividend yield is 2.54 percent.
Q6. What is the shareholding pattern of Abbott India?
Ans. As of June 2026, promoters hold approximately 74.99 percent of Abbott India, domestic institutions hold around 8.78 percent, and public shareholders hold roughly 13.41 percent. The promoter holding has remained stable over recent quarters.